0001225208-17-005433.txt : 20170302 0001225208-17-005433.hdr.sgml : 20170302 20170302191754 ACCESSION NUMBER: 0001225208-17-005433 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170228 FILED AS OF DATE: 20170302 DATE AS OF CHANGE: 20170302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dawkins Keith D CENTRAL INDEX KEY: 0001492253 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 17660920 MAIL ADDRESS: STREET 1: BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2017-02-28 0000885725 BOSTON SCIENTIFIC CORP BSX 0001492253 Dawkins Keith D 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP, Global Chief Med. Off. Common Stock 2017-02-28 4 A 0 22934.0000 0.0000 A 105384.0000 D Common Stock 2017-02-28 4 M 0 4736.0000 0.0000 A 110120.0000 D Common Stock 2017-02-28 4 F 0 11955.0000 24.5500 D 98165.0000 D Common Stock 2017-02-28 4 S 0 30000.0000 24.6378 D 68165.0000 D Deferred Stock Units 2017-02-28 4 M 0 4736.0000 0.0000 D Common Stock 4736.0000 4736.0000 D Performance Share Units 2017-02-28 4 A 0 9923.0000 0.0000 A 2018-12-31 2018-12-31 Common Stock 9923.0000 9923.0000 D On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.625 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Reflects multiple DSU awards with independent vesting schedules. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. /s/ Vance R. Brown, Attorney-in-fact 2017-03-02